Back to Search
Start Over
DPP4 promotes an immunoenhancing tumor microenvironment through exhausted CD8+ T cells with activating IL13-IL13RA2 axis in papillary thyroid cancer.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2025 Jan 03; Vol. 145, pp. 113760. Date of Electronic Publication: 2024 Dec 10. - Publication Year :
- 2025
-
Abstract
- Background: Papillary thyroid cancer (PTC) is among the most prevalent forms of endocrine malignancy with a rapid rise in incidence rates worldwide; however, the composition and characteristics of its immune microenvironment is poorly understand. Here, this work investigated the precise function of Dipeptidyl peptidase 4 (DPP4) in tumor-infiltrated T cells within PTC by investigating its role in cytokine-mediated signaling pathways.<br />Methods: TCGA and GEO data as well as human PTC specimens confirmed the expression of DPP4 in PTC. The CIBERSORT and TIMER tool were used to analyze the distribution of tumor-infiltrating immune cells in PTC. CD8+ T cells from PTC patient's peripheral blood were cultured and used in a three-dimensional model for direct co-culture with PTC tumors to investigate DPP4 function.<br />Results: Bioinformatic analyses has uncovered a significant upregulation of DPP4, which enhances the survival and migration of PTC cells in vitro. DPP4 upregulation significantly correlated with advanced grades, stages, and poor progression-free survival. DPP4 influences immune function and the exhaustion of CD8+ T cells through the IL13-IL13RA2 axis. The inhibition of DPP4 reduces CD8+ T cell exhaustion and IL13 secretion, while also blocking the IL13-IL13RA2 axis, thereby promoting the mesenchymal-to-epithelial transition of PTC cells.<br />Conclusion: Blocking DPP4 leads to the conversion of exhausted CD8+ T cells with decreased IL13 level, resulting in downregulation of IL13RA2 to promote mesenchymal-to-epithelial transition of PTC cells. This highlights DPP4 as a potential therapeutic target, particularly between CD8+ T cells and PTC cells via IL13-IL13RA2 axis, and represents a novel avenue for combined immunotherapy in PTC.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Cell Line, Tumor
Signal Transduction
Lymphocytes, Tumor-Infiltrating immunology
Dipeptidyl-Peptidase IV Inhibitors pharmacology
Dipeptidyl Peptidase 4 metabolism
Dipeptidyl Peptidase 4 genetics
Thyroid Cancer, Papillary immunology
Thyroid Cancer, Papillary genetics
Thyroid Cancer, Papillary pathology
CD8-Positive T-Lymphocytes immunology
Tumor Microenvironment immunology
Thyroid Neoplasms immunology
Thyroid Neoplasms pathology
Thyroid Neoplasms genetics
Interleukin-13 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 145
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 39662266
- Full Text :
- https://doi.org/10.1016/j.intimp.2024.113760